Efficacy News and Research

RSS

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Neuralstem, Inc. announced that it has received approval from the Food and Drug Administration (FDA) to begin dosing the third and final cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

26 Apr 2013

Renal denervation reduces blood pressure for patients not responding to drug therapy

Up to 10 per cent of patients with high blood pressure are resistant to treatment, which puts them at increased risk of cardiovascular events, including heart attacks. Clinical trials show that catheter-based renal denervation reduces blood pressure in patients who do not respond to conventional drug therapy.

26 Apr 2013

Derma Sciences initiates patient screening in DSC127 pivotal program for treatment of diabetic foot ulcers

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that patient screening has begun in the second of two Phase 3 clinical trials with the investigational topical drug candidate DSC127 for the treatment of diabetic foot ulcers.

26 Apr 2013

Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr. Jennifer Cohn, Médecins Sans Frontières

MDR-TB is tuberculosis, a mycobacterial infection, that has developed resistance to two important and powerful first-line anti-TB drugs, INH and rifampin.

26 Apr 2013

Research shows probiotics reduce the development of hepatic encephalopathy

Probiotics could emerge as a treatment plan to manage hepatic encephalopathy (HE) therapy after a new study announced at the International Liver Congress- 2013 found they significantly reduced development of the notoriously difficult-to-treat disease.

26 Apr 2013

Stem cell transplant regimen to treat neuroblastoma in children appears to be more toxic in US

The stem cell transplant regimen that was commonly used in the United States to treat advanced neuroblastoma in children appears to be more toxic than the equally effective regimen employed in Europe and Egypt, according to a new study to be presented at the 26th annual meeting of the American Society of Pediatric Hematology Oncology in Miami April 24-27.

25 Apr 2013

Cardiac risk patients treated with beta-blockers have lower rates of mortality

Patients at elevated cardiac risk who were treated with beta-blockers on the day of or following noncardiac, nonvascular surgery had significantly lower rates of 30-day mortality and cardiac illness, according to a study in the April 24 issue of JAMA.

25 Apr 2013

Studies demonstrate encouraging results for new direct-acting antiviral agents

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2013 demonstrate encouraging results in the use of new direct-acting antiviral agents (DAAs) for the treatment of hepatitis C.

25 Apr 2013

Beta blockade aids select surgery patients

Research supports the use of perioperative beta blockade in patients with cardiovascular risk factors undergoing nonvascular procedures, finding this treatment to significantly improve short-term survival.

25 Apr 2013

Mechanism of tumor suppressor p53 inactivation described

Cancer cells are a problem for the body because they multiply recklessly, refuse to die and blithely metastasize to set up shop in places where they don’t belong. One protein that keeps healthy cells from behaving this way is a tumor suppressor named p53. This protein stops potentially precancerous cells from dividing and induces suicide in those that are damaged beyond repair. Not surprisingly, p53’s critical function is disrupted in most cancers.

25 Apr 2013

Fixed-dose combination of drugs effectively lowers IOP

A fixed-dose combination of brinzolamide and brimonidine is more effective than either drug given alone for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, results of a phase III trial indicate.

25 Apr 2013

WHO highlights threat of antimalarial drug resistance in Greater Mekong subregion

On World Malaria Day, 25 April, WHO recognizes significant accomplishments in preventing and controlling malaria, including in high-burden countries in sub-Saharan Africa, but highlights the threat of antimalarial drug resistance in south-east Asia's Greater Mekong subregion, where an emergency response is now being launched.

25 Apr 2013

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia.

24 Apr 2013

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Nanogels are synthetic particles that can be used for drug delivery. They are approximately 100 nm to 200 nm in diameter, and are made from safe, biocompatible materials: a gel-like interior and a lipid exterior.

24 Apr 2013

Transformative technologies highlighted in current issue of Technology and Innovation

Improving brain function is one of the topics explored in the latest issue of Technology and Innovation - Proceedings of the National Academy of Inventors.

24 Apr 2013

Research project to identify mechanisms underlying effects of cancer drug interferon-α

The immune system plays a decisive role in the fight against tumor cells. However, when tumor cells themselves prevent activation of the immune system, the immune system fails to destroy cancer cells.

24 Apr 2013

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

24 Apr 2013

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen R&D Ireland today announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naive genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin.

24 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Mayo Clinic and Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis.

23 Apr 2013

Efficacy News and Research

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Renal denervation reduces blood pressure for patients not responding to drug therapy

Derma Sciences initiates patient screening in DSC127 pivotal program for treatment of diabetic foot ulcers

Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr. Jennifer Cohn, Médecins Sans Frontières

Research shows probiotics reduce the development of hepatic encephalopathy

Stem cell transplant regimen to treat neuroblastoma in children appears to be more toxic in US

Cardiac risk patients treated with beta-blockers have lower rates of mortality

Studies demonstrate encouraging results for new direct-acting antiviral agents

Beta blockade aids select surgery patients

Mechanism of tumor suppressor p53 inactivation described

Fixed-dose combination of drugs effectively lowers IOP

WHO highlights threat of antimalarial drug resistance in Greater Mekong subregion

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Transformative technologies highlighted in current issue of Technology and Innovation

Research project to identify mechanisms underlying effects of cancer drug interferon-α

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News